Inactive Instrument

News Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
May. 28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference	Jun. 12	AQ
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	Jun. 11	AQ
European Biosimilar Regulatory Update	Jun. 10	AQ
Corporate Presentation: June 2024	Jun. 05	PU
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	May. 29	AQ
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	May. 28	MT
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	May. 28	AQ
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	May. 28	CI
CoStar Group has room for expansion	May. 21
Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024	May. 16
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15	CI
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	May. 15	AQ
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	May. 13	MT
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	May. 13	AQ
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	May. 13	CI
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	May. 09	AQ
Outlook Therapeutics® to Present at the Retina World Congress 2024	May. 02	AQ
Outlook Therapeutics, Inc. Announces Change in Headquarters Address	May. 01	CI
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	Apr. 29	AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	Apr. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncobiologics Inc Nasdaq

Equities

US68235M2044

Summary

Filters